PMID- 16524970
OWN - NLM
STAT- MEDLINE
DCOM- 20061114
LR  - 20220330
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 17
IP  - 6
DP  - 2006 Jun
TI  - Comparison of the epidermal growth factor receptor gene and protein in primary 
      non-small-cell-lung cancer and metastatic sites: implications for treatment with 
      EGFR-inhibitors.
PG  - 981-5
AB  - BACKGROUND: Very recent studies have suggested that EGFR gene copy number and 
      expression obtained by fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC) should be used to predict which lung cancer patients 
      are expected to respond to anti-EGFR treatments. However, it is still not known 
      whether EGFR expression differs in metastases compared to primary non-small cell 
      lung cancer (NSCLC). PATIENTS AND METHODS: EGFR status was analysed by IHC and 
      FISH on tumor samples of primary NSCLC and at least one distant metastatic lesion 
      in 30 patients. RESULTS: Ten cases (33.3%) showed primary tumor/metastasis 
      discordance by IHC analysis (n = 30): in seven cases, EGFR was expressed in the 
      primary tumor but not in the metastasis, while three samples showed EGFR 
      expression in the metastasis but not in the primary tumor (Pearson correlation 
      coefficient = 0.331, P = 0.0074). By FISH (n = 26), seven (27%) cases were 
      discordant: six cases showed a high-level of EGFR polysomy in the primary tumor 
      but not in the metastasis and one case showed a high-level of EGFR polysomy in 
      the metastasis but not in the primary sample (Pearson correlation coefficient = 
      0.52, P = 0.007). CONCLUSION: EGFR expression is not stable during metastatic 
      progression in a significant proportion of NSCLC. These findings have to be 
      considered in future prospective studies.
FAU - Italiano, A
AU  - Italiano A
AD  - Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France. 
      antoineitaliano@cario.fr
FAU - Vandenbos, F Burel
AU  - Vandenbos FB
FAU - Otto, J
AU  - Otto J
FAU - Mouroux, J
AU  - Mouroux J
FAU - Fontaine, D
AU  - Fontaine D
FAU - Marcy, P-Y
AU  - Marcy PY
FAU - Cardot, N
AU  - Cardot N
FAU - Thyss, A
AU  - Thyss A
FAU - Pedeutour, F
AU  - Pedeutour F
LA  - eng
PT  - Journal Article
DEP - 20060308
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics/pathology/surgery
MH  - Drug Design
MH  - ErbB Receptors/*antagonists & inhibitors/*metabolism
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Genes, erbB-1
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*genetics/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Observer Variation
EDAT- 2006/03/10 09:00
MHDA- 2006/11/15 09:00
CRDT- 2006/03/10 09:00
PHST- 2006/03/10 09:00 [pubmed]
PHST- 2006/11/15 09:00 [medline]
PHST- 2006/03/10 09:00 [entrez]
AID - S0923-7534(19)43565-5 [pii]
AID - 10.1093/annonc/mdl038 [doi]
PST - ppublish
SO  - Ann Oncol. 2006 Jun;17(6):981-5. doi: 10.1093/annonc/mdl038. Epub 2006 Mar 8.